Michael Davidson to Humans
This is a "connection" page, showing publications Michael Davidson has written about Humans.
Connection Strength
4.003
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.030
-
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers. Am J Cardiovasc Drugs. 2025 Sep; 25(5):693-702.
Score: 0.030
-
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants. Drug Saf. 2025 Sep; 48(9):993-1004.
Score: 0.030
-
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities? Dialogues Clin Neurosci. 2025 12; 27(1):1-12.
Score: 0.029
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 Dec; 12(6):e70010.
Score: 0.029
-
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity. Curr Opin Lipidol. 2024 Dec 01; 35(6):303-309.
Score: 0.029
-
CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis. Front Endocrinol (Lausanne). 2024; 15:1359780.
Score: 0.028
-
Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence. Schizophr Bull. 2024 01 01; 50(1):14-21.
Score: 0.027
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
Score: 0.027
-
Who has poor insight, my patient suffering from schizophrenia or myself? Eur Neuropsychopharmacol. 2023 03; 68:27-29.
Score: 0.025
-
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022 08; 28(8):1672-1678.
Score: 0.025
-
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophr Bull. 2022 05 07; 48(3):609-619.
Score: 0.024
-
Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery. Expert Opin Drug Discov. 2022 05; 17(5):443-460.
Score: 0.024
-
Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2022 01 16; 23(1):34.
Score: 0.024
-
The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial. Eur Neuropsychopharmacol. 2021 10; 51:33-42.
Score: 0.023
-
The clinical black, white, and gray lessons. Curr Opin Lipidol. 2021 04 01; 32(2):151-156.
Score: 0.022
-
How I treat statin-associated side effects in an outpatient setting. Future Cardiol. 2021 10; 17(7):1249-1260.
Score: 0.022
-
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2021 01; 32(1):211-222.
Score: 0.022
-
Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
Score: 0.021
-
Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020 04; 31(2):108-110.
Score: 0.021
-
Do DSM classifications help or hinder?drug development??. Dialogues Clin Neurosci. 2020 03; 22(1):73-79.
Score: 0.021
-
The Battle of the HDL Subfractions. Cardiovasc Revasc Med. 2019 11; 20(11):943-944.
Score: 0.020
-
Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. Eur J Cancer. 2019 11; 122:12-21.
Score: 0.020
-
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. Eur J Cancer. 2019 11; 121:40-47.
Score: 0.020
-
Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression. Schizophr Res. 2020 01; 215:352-356.
Score: 0.020
-
The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. Cardiovasc Revasc Med. 2020 02; 21(2):200-204.
Score: 0.020
-
?-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. Adv Nutr. 2018 Nov 01; 9(6):688-700.
Score: 0.019
-
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. Curr Cardiol Rep. 2018 10 17; 20(12):138.
Score: 0.019
-
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):54-61.
Score: 0.018
-
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clin Colorectal Cancer. 2018 09; 17(3):223-230.
Score: 0.018
-
Clinical trials. Curr Opin Lipidol. 2018 06; 29(3):277-278.
Score: 0.018
-
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018 Jul - Aug; 12(4):898-907.e2.
Score: 0.018
-
Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharmacol Ther. 2018 03; 23(2):103-118.
Score: 0.018
-
Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. Cardiol Clin. 2018 May; 36(2):277-285.
Score: 0.018
-
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. Eur Heart J. 2018 02 14; 39(7):620-622.
Score: 0.018
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.018
-
Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
Score: 0.018
-
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. Rev Cardiovasc Med. 2018; 19(S1):S31-S46.
Score: 0.018
-
The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophr Res. 2018 07; 197:269-273.
Score: 0.018
-
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
Score: 0.017
-
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient. 2017 06; 10(3):321-334.
Score: 0.017
-
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther. 2017 May; 15(5):415-423.
Score: 0.017
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
Score: 0.017
-
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
Score: 0.017
-
The future of n-3 polyunsaturated fatty acid therapy. Curr Opin Lipidol. 2016 12; 27(6):570-578.
Score: 0.017
-
Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. JAMA Intern Med. 2016 10 01; 176(10):1530.
Score: 0.016
-
Intensive statin therapy in India: Demonstrating efficacy and safety. Indian Heart J. 2016 Nov - Dec; 68(6):756-757.
Score: 0.016
-
The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
Score: 0.016
-
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):905-914.
Score: 0.016
-
Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72.
Score: 0.015
-
Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
Score: 0.015
-
A population-based longitudinal study of suicide risk in male schizophrenia patients: Proximity to hospital discharge and the moderating effect of premorbid IQ. Schizophr Res. 2015 Dec; 169(1-3):159-164.
Score: 0.015
-
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015 Sep 02; 14:98.
Score: 0.015
-
AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
Score: 0.015
-
Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. EBioMedicine. 2015 Apr; 2(4):284.
Score: 0.015
-
Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks. Regul Toxicol Pharmacol. 2014 Dec; 70 Suppl 2:S143-57.
Score: 0.014
-
Combination therapy with statins: who benefits? Endocrinol Metab Clin North Am. 2014 Dec; 43(4):993-1006.
Score: 0.014
-
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2014 Sep; 12(9):1045-54.
Score: 0.014
-
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 01; 36(8):1211-22.
Score: 0.014
-
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
Score: 0.014
-
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
Score: 0.014
-
RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2014 Apr; 106(4):dju019.
Score: 0.014
-
Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):439-52.
Score: 0.014
-
Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec; 24(6):467-74.
Score: 0.013
-
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014 Jan-Feb; 8(1):94-106.
Score: 0.013
-
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013; 9:563-73.
Score: 0.013
-
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol. 2013 Nov; 10(11):618-9.
Score: 0.013
-
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
Score: 0.013
-
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
Score: 0.013
-
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 2013 Oct; 230(2):322-9.
Score: 0.013
-
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
Score: 0.013
-
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013 Sep-Oct; 7(5):423-32.
Score: 0.013
-
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
Score: 0.013
-
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013 May-Jun; 7(3 Suppl):S11-5.
Score: 0.013
-
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index =27 kg/m(2). Am J Cardiol. 2013 Apr 15; 111(8):1131-8.
Score: 0.013
-
Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure? J Am Coll Cardiol. 2012 Dec 25; 60(25):2616-7.
Score: 0.013
-
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72.
Score: 0.013
-
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):1B-3B.
Score: 0.012
-
Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):43B-49B.
Score: 0.012
-
Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep; 73(9):e1168-74.
Score: 0.012
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
Score: 0.012
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
Score: 0.012
-
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012 Nov-Dec; 6(6):573-84.
Score: 0.012
-
Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol. 2011 Dec; 22(6):437-44.
Score: 0.012
-
The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
Score: 0.012
-
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011 Sep-Oct; 5(5):338-67.
Score: 0.011
-
The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):1B-2B.
Score: 0.011
-
Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):33B-41B.
Score: 0.011
-
Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
Score: 0.011
-
Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011 Feb; 13(1):95-100.
Score: 0.011
-
Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin. 2011 Feb; 29(1):105-22.
Score: 0.011
-
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011 Mar-Apr; 5(2):76-81.
Score: 0.011
-
Apolipoprotein A-I therapy promise, challenges, and disappointment. J Am Coll Cardiol. 2011 Mar 01; 57(9):1120-1.
Score: 0.011
-
CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res. 2010 Dec; 124(1-3):231-5.
Score: 0.011
-
High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol. 2010 Sep-Oct; 4(5):359-64.
Score: 0.011
-
Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
Score: 0.011
-
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
Score: 0.011
-
Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. J Clin Lipidol. 2010 Jan-Feb; 4(1):72-3; discussion 74.
Score: 0.010
-
Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33.
Score: 0.010
-
Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ. 2010; 13(3):500-7.
Score: 0.010
-
A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010; 10(5):305-14.
Score: 0.010
-
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
Score: 0.010
-
Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.
Score: 0.010
-
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):3E-9E.
Score: 0.010
-
Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
Score: 0.010
-
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time. J Fam Pract. 2009 Nov; 58(11 Suppl Urgent):S26-31.
Score: 0.010
-
Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol. 2009 Oct 01; 104(7):936-42.
Score: 0.010
-
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
Score: 0.010
-
Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
Score: 0.010
-
Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al. Cardiovasc Drugs Ther. 2009 Jun; 23(3):187-8.
Score: 0.010
-
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun; 166(6):675-82.
Score: 0.010
-
Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):183-8.
Score: 0.010
-
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. Trends Cardiovasc Med. 2009 Apr; 19(3):94-9.
Score: 0.010
-
Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
Score: 0.010
-
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med. 2009 Jan; 122(1 Suppl):S51-9.
Score: 0.010
-
A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009 Jan-Feb; 29(1):2-12.
Score: 0.010
-
Updating the assessment of cardiac risk: beyond Framingham. Rev Cardiovasc Med. 2009; 10(2):63-71.
Score: 0.010
-
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
Score: 0.010
-
Refractive errors and schizophrenia. Schizophr Res. 2009 Feb; 107(2-3):238-41.
Score: 0.009
-
Atherosclerosis surrogate imaging trials come of age: for better or for worse? Curr Cardiol Rep. 2008 Nov; 10(6):521-5.
Score: 0.009
-
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract. 2008 Nov; 14(8):985-92.
Score: 0.009
-
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol. 2008 Sep; 28(9):1582-3.
Score: 0.009
-
Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008 Jul; 6(6):781-3.
Score: 0.009
-
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med. 2008 Jul; 75(7):479-82, 486-8, 490-1.
Score: 0.009
-
Should every patient with diabetes receive a statin? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):398-401.
Score: 0.009
-
Introduction. U.S. incidence of coronary artery disease. Am J Cardiol. 2008 Jun 16; 101(12A):1F-2F.
Score: 0.009
-
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
Score: 0.009
-
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F.
Score: 0.009
-
High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008 May; 57(5 Suppl High-Dose):S29-36.
Score: 0.009
-
Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. Am J Cardiol. 2008 Apr 17; 101(8A):1B-2B.
Score: 0.009
-
Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
Score: 0.009
-
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
Score: 0.009
-
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008 Apr 22; 117(16):2123-30.
Score: 0.009
-
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
Score: 0.009
-
Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol. 2008 Apr 01; 101(7):986-91.
Score: 0.009
-
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008; 8(2):69-81.
Score: 0.009
-
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008; 28(10):615-23.
Score: 0.009
-
High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007 Dec 03; 100(11 A):n32-40.
Score: 0.009
-
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007 Dec; 13 Suppl 10:S260-9.
Score: 0.009
-
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007 Dec; 13 Suppl 10:S270-5.
Score: 0.009
-
Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther. 2007 Nov; 29(11):2385-94.
Score: 0.009
-
Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data. Int J Clin Pract. 2007 Oct; 61(10):1634-42.
Score: 0.009
-
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007 Oct; 8(15):2569-78.
Score: 0.009
-
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Jul; 29(7):1354-67.
Score: 0.009
-
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin. 2007 May; 23(5):1121-30.
Score: 0.009
-
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul; 93(1-3):117-30.
Score: 0.009
-
Safety of aggressive lipid management. J Am Coll Cardiol. 2007 May 01; 49(17):1753-62.
Score: 0.008
-
Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci. 2007 Jun 15; 257(1-2):177-81.
Score: 0.008
-
Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr. 2007 Mar; 85(3):724-34.
Score: 0.008
-
Squalene synthase inhibition: a novel target for the management of dyslipidemia. Curr Atheroscler Rep. 2007 Jan; 9(1):78-80.
Score: 0.008
-
Reducing the risk of stroke through appropriate targets and treatments. Prev Cardiol. 2007; 10(4):215-21.
Score: 0.008
-
Rosuvastatin in elderly patients. Drugs Aging. 2007; 24(11):933-44.
Score: 0.008
-
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
Score: 0.008
-
Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
Score: 0.008
-
Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
Score: 0.008
-
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006 Nov 07; 48(9):1774-81.
Score: 0.008
-
Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006 Nov; 12(15 Suppl):S405-11.
Score: 0.008
-
Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 2006 Oct; 23(10):1158-9.
Score: 0.008
-
Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother. 2006 Sep; 7(13):1701-14.
Score: 0.008
-
How low to target LDL? Nat Clin Pract Endocrinol Metab. 2006 Aug; 2(8):414-5.
Score: 0.008
-
Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
Score: 0.008
-
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
Score: 0.008
-
Inhaled human insulin: an inspiration for patients with diabetes mellitus? Cleve Clin J Med. 2006 Jun; 73(6):569-78.
Score: 0.008
-
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
Score: 0.008
-
Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006 Aug 21; 98(4A):27i-33i.
Score: 0.008
-
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res. 2006 Jul; 85(1-3):49-57.
Score: 0.008
-
Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med. 2006 Apr; 21(4):320-6.
Score: 0.008
-
Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006 Apr 17; 97(8A):32C-43C.
Score: 0.008
-
Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol. 2006 Feb; 28(2):193-207.
Score: 0.008
-
Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
Score: 0.008
-
Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized? Schizophr Bull. 2026 Jan 16; 52(1).
Score: 0.008
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
Score: 0.008
-
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
Score: 0.008
-
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005 Dec; 62(12):1297-304.
Score: 0.008
-
Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):455-62.
Score: 0.008
-
Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006 Jan 15; 97(2):223-8.
Score: 0.008
-
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
Score: 0.008
-
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol. 2005 Nov 07; 96(9A):59K-64K; discussion 34K-35K.
Score: 0.008
-
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
Score: 0.008
-
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
Score: 0.008
-
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS Drugs. 2026 Jan; 40(1):99-109.
Score: 0.008
-
Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005 Sep; 3(5):789-820.
Score: 0.008
-
Management of dyslipidemia in patients with complicated metabolic syndrome. Am J Cardiol. 2005 Aug 22; 96(4A):22E-25E.
Score: 0.008
-
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 Aug 19; 68(1):e116.
Score: 0.008
-
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
Score: 0.008
-
Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005 Jun; 24(3):189-99.
Score: 0.007
-
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2005 Jun; 27(6):715-27.
Score: 0.007
-
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. Arterioscler Thromb Vasc Biol. 2025 Jul; 45(7):1310-1315.
Score: 0.007
-
Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation. 2005 May 10; 111(18):2280-1.
Score: 0.007
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
Score: 0.007
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
Score: 0.007
-
High-dose statins in acute coronary syndromes. JAMA. 2005 Jan 05; 293(1):38; author reply 38-9.
Score: 0.007
-
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
Score: 0.007
-
Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus. Am J Cardiol. 2005 Jan 01; 95(1):123-6.
Score: 0.007
-
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
Score: 0.007
-
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Prev Cardiol. 2005; 8(4):244-9.
Score: 0.007
-
Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 Nov 23; 63(10):1902-7.
Score: 0.007
-
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf. 2004 Nov; 3(6):547-57.
Score: 0.007
-
Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry. 2004 Nov; 65(11):1546-9.
Score: 0.007
-
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimers Res Ther. 2024 Oct 16; 16(1):228.
Score: 0.007
-
Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case-control comparison with patients testing negative. Lancet Psychiatry. 2024 10; 11(10):828-838.
Score: 0.007
-
Evidence for altered positional specificity of LCAT in vivo: studies with docosahexaenoic acid feeding in humans. J Lipid Res. 2004 Dec; 45(12):2245-51.
Score: 0.007
-
Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis. 2004 Sep-Oct; 47(2):73-104.
Score: 0.007
-
Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. Postgrad Med. 2004 Sep; 116(3 Suppl):7-12.
Score: 0.007
-
Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug; 15(4):423-31.
Score: 0.007
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
Score: 0.007
-
Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria. Schizophr Res. 2024 09; 271:246-252.
Score: 0.007
-
Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 Oct; 87:18-23.
Score: 0.007
-
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol. 2004 Jul; 19(4):374-9.
Score: 0.007
-
Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004 Jul; 161(7):1219-23.
Score: 0.007
-
Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004 Jun 03; 93(11A):3C-11C.
Score: 0.007
-
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024 05 29; 120(7):678-680.
Score: 0.007
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
Score: 0.007
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.007
-
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004 Apr 15; 116(8):546-54.
Score: 0.007
-
Plasma lipid levels in Alzheimer's disease patients treated by Donepezil hydrochloride: a cross-sectional study. Arch Gerontol Geriatr. 2004 Jan-Feb; 38(1):61-8.
Score: 0.007
-
Biologic therapies for dyslipidemia. Curr Atheroscler Rep. 2004 Jan; 6(1):69-72.
Score: 0.007
-
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2024 01 01; 35(1):74-84.
Score: 0.007
-
Newer pharmaceutical agents to treat lipid disorders. Curr Cardiol Rep. 2003 Nov; 5(6):463-9.
Score: 0.007
-
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clin Cardiol. 2003 Nov; 26(11):509-14.
Score: 0.007
-
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther. 2003 Nov; 25(11):2738-53.
Score: 0.007
-
Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003 Oct 27; 163(19):2394-5.
Score: 0.007
-
Usefulness of Carotid Ultrasound Screening in Primary Cardiovascular Prevention: A Systematic Review. Curr Probl Cardiol. 2024 Jan; 49(1 Pt C):102147.
Score: 0.007
-
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study. Clin Lung Cancer. 2024 01; 25(1):e35-e42.
Score: 0.007
-
Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs. Int J Vitam Nutr Res. 2003 Oct; 73(5):357-68.
Score: 0.007
-
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
Score: 0.007
-
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16; 42(2):398-9; author reply 399.
Score: 0.007
-
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophr Bull. 2023 07 04; 49(4):903-913.
Score: 0.007
-
The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003 Jul; 169(1):113-20.
Score: 0.007
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
Score: 0.006
-
Combination lipid-lowering therapy in diabetes. Curr Diab Rep. 2003 Jun; 3(3):263-8.
Score: 0.006
-
Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003 May; 1(1):11-21.
Score: 0.006
-
A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2023 08; 73:65-74.
Score: 0.006
-
Long-term effects of Roluperidone on negative symptoms of schizophrenia. Schizophr Res. 2023 05; 255:9-13.
Score: 0.006
-
Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. J Nutr. 2003 Mar; 133(3):808-13.
Score: 0.006
-
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):148-155.
Score: 0.006
-
Perceived patient threat and neuroleptic dosage. J Nerv Ment Dis. 2003 Feb; 191(2):129-30.
Score: 0.006
-
Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial. JAMA Cardiol. 2023 02 01; 8(2):177-181.
Score: 0.006
-
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023 03; 10(3):197-208.
Score: 0.006
-
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Cardiovasc Nurs. 2003 Jan-Mar; 18(1):44-9; quiz 75-6.
Score: 0.006
-
Efficacy of over-the-counter nutritional supplements. Curr Atheroscler Rep. 2003 Jan; 5(1):15-21.
Score: 0.006
-
Lipid management and the elderly. Prev Cardiol. 2003; 6(3):128-33; quiz 134-5.
Score: 0.006
-
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
Score: 0.006
-
Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. Am J Psychiatry. 2002 Dec; 159(12):2021-6.
Score: 0.006
-
A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry. 2002 Dec; 159(12):2027-35.
Score: 0.006
-
Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002 Nov 20; 90(10B):50K-60K.
Score: 0.006
-
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine-Brief Report. Arterioscler Thromb Vasc Biol. 2022 12; 42(12):1461-1467.
Score: 0.006
-
Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 2002 Sep; 1(3):207-12.
Score: 0.006
-
Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. J Infect Dis. 2002 Oct 01; 186(7):1013-8.
Score: 0.006
-
Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial. J Clin Psychiatry. 2022 08 01; 83(5).
Score: 0.006
-
Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022 08; 171:44-54.
Score: 0.006
-
A look to the future: new treatment guidelines and a perspective on statins. Am J Med. 2002 Jun 03; 112 Suppl 8A:34S-41S.
Score: 0.006
-
Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. AIDS. 2002 Mar 29; 16(5):757-65.
Score: 0.006
-
A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction. Am J Cardiol. 2002 Mar 07; 89(5A):1C-2C.
Score: 0.006
-
Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
Score: 0.006
-
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Mar; 11(3):125-41.
Score: 0.006
-
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 01; 89(3):268-75.
Score: 0.006
-
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Jan; 11(1):125-41.
Score: 0.006
-
A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther. 2002 Jan; 24(1):112-25.
Score: 0.006
-
Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19(3):169-78.
Score: 0.006
-
Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
Score: 0.006
-
Familial clustering of psychiatric disorders and low IQ. Psychol Med. 2023 May; 53(7):2878-2884.
Score: 0.006
-
Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry. 2001 Oct; 58(10):959-64.
Score: 0.006
-
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct; 76(10):971-82.
Score: 0.006
-
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct; 15(5):629-648.
Score: 0.006
-
Misreporting of Results of Research in Psychiatry. Schizophr Bull. 2021 08 21; 47(5):1254-1260.
Score: 0.006
-
Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr. 2001 Aug; 20(4):307-19.
Score: 0.006
-
Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs. Am J Psychiatry. 2021 10 01; 178(10):932-940.
Score: 0.006
-
Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. Schizophr Bull. 2021 07 08; 47(4):1077-1087.
Score: 0.006
-
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther. 2001 Jul; 6(3):219-29.
Score: 0.006
-
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 Jun; 24(6):467-74.
Score: 0.006
-
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001 May 30; 50(1-2):89-93.
Score: 0.006
-
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 05 29; 397(10289):2060-2069.
Score: 0.006
-
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
Score: 0.006
-
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer. 2021 06; 156:147-150.
Score: 0.006
-
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr 01; 110(5):352-60.
Score: 0.006
-
Acute day units for mental health crises: a qualitative study of service user and staff views and experiences. BMC Psychiatry. 2021 03 10; 21(1):146.
Score: 0.006
-
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. Am J Cardiol. 2001 Feb 16; 87(4A):1A-7A.
Score: 0.006
-
Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
Score: 0.005
-
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001; 61(2):197-206.
Score: 0.005
-
Long-term safety of risperidone. J Clin Psychiatry. 2001; 62 Suppl 21:26-8.
Score: 0.005
-
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
Score: 0.005
-
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2021 02 25; 2(2):224-235.
Score: 0.005
-
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 2000 Nov 27; 160(21):3315-25.
Score: 0.005
-
Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs. 2000 Nov; 9(11):2663-71.
Score: 0.005
-
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
Score: 0.005
-
Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med. 2000 Oct; 23(5):300-10.
Score: 0.005
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2000 Oct; 10(5):253-62.
Score: 0.005
-
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
Score: 0.005
-
Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial. Schizophr Bull. 2020 07 08; 46(4):964-970.
Score: 0.005
-
Schizotypal traits and neuropsychological performance: The role of processing speed. Schizophr Res. 2020 09; 223:128-134.
Score: 0.005
-
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000 Jun; 15(6):506-14.
Score: 0.005
-
Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. Lipids Health Dis. 2020 May 30; 19(1):117.
Score: 0.005
-
Efficacy of antiobesity therapies. Am J Clin Nutr. 2000 Mar; 71(3):844.
Score: 0.005
-
Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort. Eur Neuropsychopharmacol. 2020 03; 32:131-135.
Score: 0.005
-
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci Transl Med. 2020 01 29; 12(528).
Score: 0.005
-
Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep. 2000 Jan; 2(1):14-9.
Score: 0.005
-
Antidepressants and the Risk of Dementia: Appropriate Consideration of Confounding by Indication. Am J Geriatr Psychiatry. 2020 04; 28(4):499-500.
Score: 0.005
-
Analysis of Minnesota Multiphasic Personality Inventory-2 profiles of prospective anonymous oocyte donors in relation to the outcome of the donor selection process. Fertil Steril. 1999 Dec; 72(6):1066-72.
Score: 0.005
-
Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health. 1999 Nov; 89(11):1701-7.
Score: 0.005
-
Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
Score: 0.005
-
Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999 Sep 13; 159(16):1893-900.
Score: 0.005
-
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol. 2019 Nov - Dec; 13(6):997-1007.e8.
Score: 0.005
-
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 09; 211:103-104.
Score: 0.005
-
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
Score: 0.005
-
Effects of dietary inulin on serum lipids. J Nutr. 1999 07; 129(7 Suppl):1474S-7S.
Score: 0.005
-
Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. Arch Intern Med. 1999 Jun 28; 159(12):1331-8.
Score: 0.005
-
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
Score: 0.005
-
Exposure to Antidepressant Medication and the Risk of Incident Dementia. Am J Geriatr Psychiatry. 2019 11; 27(11):1177-1188.
Score: 0.005
-
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials. Clin Oncol (R Coll Radiol). 2019 09; 31(9):621-629.
Score: 0.005
-
Understanding the association between advanced paternal age and schizophrenia and bipolar disorder. Psychol Med. 2020 02; 50(3):431-437.
Score: 0.005
-
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
Score: 0.005
-
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 2019 04; 206:325-332.
Score: 0.005
-
A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women. J Nutr. 1998 Nov; 128(11):1927-32.
Score: 0.005
-
Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med. 1998 Nov-Dec; 7(6):569-74.
Score: 0.005
-
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
Score: 0.005
-
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
Score: 0.005
-
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clin Chem. 2018 11; 64(11):1626-1635.
Score: 0.005
-
Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998 Aug 18; 98(7):628-33.
Score: 0.005
-
Peer-supported self-management for people discharged from a mental health crisis team: a randomised controlled trial. Lancet. 2018 08 04; 392(10145):409-418.
Score: 0.005
-
Analysis of shared heritability in common disorders of the brain. Science. 2018 06 22; 360(6395).
Score: 0.005
-
Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun; 79(3).
Score: 0.005
-
What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis? Am J Cardiol. 1998 Apr 23; 81(8A):80F-83F.
Score: 0.005
-
Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. Am J Clin Nutr. 1998 Mar; 67(3):367-76.
Score: 0.005
-
Risk of hospitalization for psychiatric disorders among siblings and parents of probands with psychotic or affective disorders: A population-based study. Eur Neuropsychopharmacol. 2018 03; 28(3):436-443.
Score: 0.004
-
Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. J Am Coll Nutr. 1997 Dec; 16(6):578-83.
Score: 0.004
-
A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis. Am J Psychiatry. 2018 04 01; 175(4):351-358.
Score: 0.004
-
The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res. 1997 Oct 30; 27(2-3):211-8.
Score: 0.004
-
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018 Mar - Apr; 12(2):321-330.
Score: 0.004
-
Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. Int J Geriatr Psychiatry. 1997 Oct; 12(10):1001-7.
Score: 0.004
-
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2017 Oct; 42(5):815-825.
Score: 0.004
-
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 1997 Sep 15; 80(6):797-8.
Score: 0.004
-
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut. 2018 10; 67(10):1780-1792.
Score: 0.004
-
Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
Score: 0.004
-
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol. 1997 Aug 01; 80(3):347-8.
Score: 0.004
-
Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
Score: 0.004
-
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 1997 Jun 09; 157(11):1186-92.
Score: 0.004
-
No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. Am J Cardiovasc Drugs. 2017 Jun; 17(3):251-260.
Score: 0.004
-
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 1997 Jun; 16(3):236-43.
Score: 0.004
-
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997 Jun 01; 79(11):1475-81.
Score: 0.004
-
Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol. 2017 May - Jun; 11(3):739-748.
Score: 0.004
-
Characteristics of elderly psychiatric patients retained in a state hospital during downsizing: a prospective study with replication. Int J Geriatr Psychiatry. 1997 Apr; 12(4):474-80.
Score: 0.004
-
Symptom severity and cognitive impairment in chronically hospitalised geriatric patients with affective disorders. Br J Psychiatry. 1997 Apr; 170:369-74.
Score: 0.004
-
Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2017 12; 190:74-76.
Score: 0.004
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
Score: 0.004
-
Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-13-S2-16.
Score: 0.004
-
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997 Jan 01; 79(1):38-42.
Score: 0.004
-
Verbal fluency deficits in geriatric and nongeriatric chronic schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997; 9(4):584-90.
Score: 0.004
-
Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res. 1996 Dec 15; 22(3):223-31.
Score: 0.004
-
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 01; 174(3):216-229.
Score: 0.004
-
The association between premorbid cognitive ability and social functioning and suicide among young men: A historical-prospective cohort study. Eur Neuropsychopharmacol. 2017 01; 27(1):1-7.
Score: 0.004
-
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
Score: 0.004
-
Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry. 1996 Oct; 153(10):1274-9.
Score: 0.004
-
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996 Oct; 23(5 Suppl 12):40-7.
Score: 0.004
-
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016 Nov - Dec; 10(6):1442-1451.e4.
Score: 0.004
-
Has deinstitutionalization affected inpatient suicide? Psychiatric inpatient suicide rates between 1990 and 2013 in Israel. Schizophr Res. 2016 May; 173(1-2):75-8.
Score: 0.004
-
Efficacy of the National Cholesterol Education Program Step I diet. A randomized trial incorporating quick-service foods. Arch Intern Med. 1996 Feb 12; 156(3):305-12.
Score: 0.004
-
Symptom stability in geriatric chronic schizophrenic inpatients: a one-year follow-up study. Biol Psychiatry. 1996 Jan 15; 39(2):92-9.
Score: 0.004
-
Directional memory arises from long-lived cytoskeletal asymmetries in polarized chemotactic cells. Proc Natl Acad Sci U S A. 2016 Feb 02; 113(5):1267-72.
Score: 0.004
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 04; 334(1):1-6.
Score: 0.004
-
A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr. 1996 Jan; 63(1):96-102.
Score: 0.004
-
Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA Psychiatry. 2016 Jan; 73(1):48-55.
Score: 0.004
-
Discontinuity in the genetic and environmental causes of the intellectual disability spectrum. Proc Natl Acad Sci U S A. 2016 01 26; 113(4):1098-103.
Score: 0.004
-
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol. 2016 Feb; 77(2):375-83.
Score: 0.004
-
Demographic, Behavioral, and Psychiatric Risk Factors for Suicide. Crisis. 2016 Mar; 37(2):104-11.
Score: 0.004
-
Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. J Clin Lipidol. 2016 Mar-Apr; 10(2):314-22.
Score: 0.004
-
Risk of completed suicide in 89,049 young males assessed by a mental health professional. Eur Neuropsychopharmacol. 2016 Feb; 26(2):341-349.
Score: 0.004
-
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
Score: 0.004
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33.
Score: 0.004
-
The cost of cognitive impairment in schizophrenia. Schizophr Res. 1995 Sep; 17(1):1-3.
Score: 0.004
-
Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment. Schizophr Res. 1995 Sep; 17(1):15-24.
Score: 0.004
-
Actin depletion initiates events leading to granule secretion at the immunological synapse. Immunity. 2015 May 19; 42(5):864-76.
Score: 0.004
-
Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. Atherosclerosis. 2015 Jul; 241(1):92-9.
Score: 0.004
-
The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry. 1995 May; 166(5):630-3.
Score: 0.004
-
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015 Jun; 14(6):935-55.
Score: 0.004
-
Live-cell multiphoton fluorescence correlation spectroscopy with an improved large Stokes shift fluorescent protein. Mol Biol Cell. 2015 Jun 01; 26(11):2054-66.
Score: 0.004
-
The association between negative symptoms, psychotic experiences and later schizophrenia: a population-based longitudinal study. PLoS One. 2015; 10(3):e0119852.
Score: 0.004
-
Microtubule-dependent transport and dynamics of vimentin intermediate filaments. Mol Biol Cell. 2015 May 01; 26(9):1675-86.
Score: 0.004
-
The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces together. Biol Psychiatry. 2015 Dec 01; 78(11):786-93.
Score: 0.004
-
Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995 Feb; 152(2):197-207.
Score: 0.004
-
Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. Cardiovasc Drugs Ther. 2015 Feb; 29(1):41-50.
Score: 0.004
-
Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. J Neuropsychiatry Clin Neurosci. 1995; 7(2):207-12.
Score: 0.004
-
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014 Dec 16; 64(23):2525-40.
Score: 0.004
-
Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest. Ann Thorac Surg. 2014 Dec; 98(6):2215-6.
Score: 0.004
-
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.
Score: 0.004
-
ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec; 237(2):705-10.
Score: 0.004
-
Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med. 1994 Oct 10; 154(19):2209-14.
Score: 0.004
-
Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015 Feb 14; 36(7):449-56.
Score: 0.004
-
The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
Score: 0.003
-
Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population. Echocardiography. 2015 Feb; 32(2):264-70.
Score: 0.003
-
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med. 1994 Jun 06; 96(6A):37S-40S.
Score: 0.003
-
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med. 1994 Jun 06; 96(6A):41S-44S.
Score: 0.003
-
Health coaching for low back pain: a systematic review of the literature. Int J Clin Pract. 2014 Aug; 68(8):950-62.
Score: 0.003
-
A contractile and counterbalancing adhesion system controls the 3D shape of crawling cells. J Cell Biol. 2014 Apr 14; 205(1):83-96.
Score: 0.003
-
The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. J Infect Dis. 1994 Apr; 169(4):792-800.
Score: 0.003
-
Microtubule-dependent transport of vimentin filament precursors is regulated by actin and by the concerted action of Rho- and p21-activated kinases. FASEB J. 2014 Jul; 28(7):2879-90.
Score: 0.003
-
Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Hum Mol Genet. 2014 Jun 15; 23(12):3166-79.
Score: 0.003
-
Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. Rev Cardiovasc Med. 2014; 15(1):1-10.
Score: 0.003
-
Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Dec 21; 15:108.
Score: 0.003
-
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
Score: 0.003
-
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
Score: 0.003
-
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8942-6.
Score: 0.003
-
Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014 Jan; 147(1):117-26.
Score: 0.003
-
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.
Score: 0.003
-
Myosin II-mediated focal adhesion maturation is tension insensitive. PLoS One. 2013; 8(7):e70652.
Score: 0.003
-
Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study. Genet Epidemiol. 2013 Nov; 37(7):751-7.
Score: 0.003
-
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
Score: 0.003
-
Efficacy of dexmedetomidine compared with midazolam for sedation in adult intensive care patients: a systematic review. Br J Anaesth. 2013 Nov; 111(5):703-10.
Score: 0.003
-
Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 1993 Jun; 16(2):313-38.
Score: 0.003
-
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013 Nov; 39(6):1230-41.
Score: 0.003
-
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 Jun; 147(1):132-139.
Score: 0.003
-
Antioxidants and lipid metabolism. Implications for the present and direction for the future. Am J Cardiol. 1993 Feb 25; 71(6):32B-36B.
Score: 0.003
-
Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013 Apr; 34(13):962-71.
Score: 0.003
-
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993 Feb; 46(2):151-63.
Score: 0.003
-
Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. Schizophr Bull. 1993; 19(4):723-32.
Score: 0.003
-
Effect of m-chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects. Biol Psychiatry. 1992 Dec 01; 32(11):1055-61.
Score: 0.003
-
Family history of schizophrenia and bipolar disorder as risk factors for autism. Arch Gen Psychiatry. 2012 Nov; 69(11):1099-1103.
Score: 0.003
-
Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res. 2012 Dec; 142(1-3):129-36.
Score: 0.003
-
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
Score: 0.003
-
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012 Oct; 51(4):314-24.
Score: 0.003
-
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
Score: 0.003
-
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
Score: 0.003
-
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 Jul 15; 167(1):225-31.
Score: 0.003
-
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag. 2012; 8:31-8.
Score: 0.003
-
Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry. 2012 May; 69(5):467-75.
Score: 0.003
-
Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. Vaccine. 1992; 10 Suppl 1:S119-20.
Score: 0.003
-
Polish Lipid Association--a strong response to the problem of lipid disorders in Poland and Central and Eastern Europe. J Clin Lipidol. 2012 Mar-Apr; 6(2):105-7.
Score: 0.003
-
An enhanced monomeric blue fluorescent protein with the high chemical stability of the chromophore. PLoS One. 2011; 6(12):e28674.
Score: 0.003
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.003
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
Score: 0.003
-
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab. 2012 Jan; 97(1):E110-4.
Score: 0.003
-
Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov; 148(11):1474-86.
Score: 0.003
-
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991 Oct; 48(10):910-3.
Score: 0.003
-
Marine oil capsule therapy for the treatment of hyperlipidemia. Arch Intern Med. 1991 Sep; 151(9):1732-40.
Score: 0.003
-
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
Score: 0.003
-
The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am. 1991 Jun; 14(2):375-84.
Score: 0.003
-
The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Psychiatr Clin North Am. 1991 Jun; 14(2):461-82.
Score: 0.003
-
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
Score: 0.003
-
The editor's roundtable: JUPITER follow-up. Am J Cardiol. 2011 May 15; 107(10):1549-57.
Score: 0.003
-
Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
Score: 0.003
-
The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. JAMA. 1991 Apr 10; 265(14):1833-9.
Score: 0.003
-
Diagnostic and pharmacological approaches in Alzheimer's disease. Drugs Aging. 1991 Mar; 1(2):144-62.
Score: 0.003
-
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol. 2011 May-Jun; 5(3):141-151.
Score: 0.003
-
Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 Mar-Apr; 5(2):66-75.
Score: 0.003
-
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
Score: 0.003
-
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry. 1991 Jan; 48(1):73-6.
Score: 0.003
-
Cholinergic strategies in the treatment of Alzheimer's disease. Acta Psychiatr Scand Suppl. 1991; 366:47-51.
Score: 0.003
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
Score: 0.003
-
Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A. 2010 Jun 08; 107(23):10584-9.
Score: 0.003
-
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010 Nov; 213(1):1-7.
Score: 0.003
-
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
Score: 0.003
-
The membrane-associated protein, supervillin, accelerates F-actin-dependent rapid integrin recycling and cell motility. Traffic. 2010 Jun; 11(6):782-99.
Score: 0.003
-
Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg. 2010 Jan; 89(1):72-80; discussion p 80.
Score: 0.003
-
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
Score: 0.003
-
Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(6):879-84.
Score: 0.003
-
Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(3):271-87.
Score: 0.003
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.003
-
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010 Jan; 71(1):58-65.
Score: 0.003
-
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec; 115(2-3):97-103.
Score: 0.003
-
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.
Score: 0.003
-
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2009 Sep 29; 54(14):1336-63.
Score: 0.003
-
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. Circulation. 2009 Sep 29; 120(13):e100-26.
Score: 0.003
-
Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care. 2009 Oct; 32(10):1916-20.
Score: 0.002
-
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
Score: 0.002
-
Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL. Obesity (Silver Spring). 2009 Dec; 17(12):2142-8.
Score: 0.002
-
The editor's roundtable: the JUPITER trial--initial results and clinical implications. Am J Cardiol. 2009 May 15; 103(10):1417-25.
Score: 0.002
-
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18; 301(11):1131-9.
Score: 0.002
-
Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009 May; 32(5):932-7.
Score: 0.002
-
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May; 53(5):741-50.
Score: 0.002
-
Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA. 1989 Feb 03; 261(5):715-8.
Score: 0.002
-
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Dis Assoc Disord. 1989; 3(4):224-7.
Score: 0.002
-
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009; 29(4):215-29.
Score: 0.002
-
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov; 26(4):547-60.
Score: 0.002
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
Score: 0.002
-
The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. Am J Cardiol. 2008 Sep 01; 102(5):559-67.
Score: 0.002
-
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010 May; 36(3):504-9.
Score: 0.002
-
The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
Score: 0.002
-
Religious education and midlife observance are associated with dementia three decades later in Israeli men. J Clin Epidemiol. 2008 Nov; 61(11):1161-8.
Score: 0.002
-
A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry. 1988 Jun; 45(6):561-3.
Score: 0.002
-
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
Score: 0.002
-
Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes. 2008 Aug; 57(8):2022-7.
Score: 0.002
-
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008 May; 9(7):1237-48.
Score: 0.002
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
Score: 0.002
-
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24.
Score: 0.002
-
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22.
Score: 0.002
-
Endocrine changes in Alzheimer's disease. Endocrinol Metab Clin North Am. 1988 Mar; 17(1):149-57.
Score: 0.002
-
Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008 Jan; 21(1):92-7.
Score: 0.002
-
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34.
Score: 0.002
-
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008 Mar; 197(1):12-24.
Score: 0.002
-
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
Score: 0.002
-
Impaired reading comprehension and mathematical abilities in male adolescents with average or above general intellectual abilities are associated with comorbid and future psychopathology. J Nerv Ment Dis. 2007 Nov; 195(11):883-90.
Score: 0.002
-
Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men. Int J Vitam Nutr Res. 2007 Sep; 77(5):347-56.
Score: 0.002
-
Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes. 2007 Mar; 56(3):849-55.
Score: 0.002
-
Type 2 diabetes and cardiovascular disease: reducing the risk. J Manag Care Pharm. 2007 Mar; 13(2 Suppl A):S2-15; quiz S16-7.
Score: 0.002
-
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 06; 296(21):2572-81.
Score: 0.002
-
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006 Nov 07; 48(9):1782-90.
Score: 0.002
-
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J. 2006 Nov; 152(5):976-81.
Score: 0.002
-
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
Score: 0.002
-
Advancing paternal age and autism. Arch Gen Psychiatry. 2006 Sep; 63(9):1026-32.
Score: 0.002
-
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006 Jul; 85(1-3):254-65.
Score: 0.002
-
Mitral valve prolapse: recent advances in diagnosis and therapy. Compr Ther. 1986 Jun; 12(6):21-32.
Score: 0.002
-
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
Score: 0.002
-
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006 Mar 23; 354(12):1253-63.
Score: 0.002
-
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol. 2006 Mar 15; 22(4):315-22.
Score: 0.002
-
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15; 97(8):1198-205.
Score: 0.002
-
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17; 97(8A):89C-94C.
Score: 0.002
-
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
Score: 0.002
-
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005 Nov; 13(11):991-8.
Score: 0.002
-
C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005 Aug 30; 112(9):1289-95.
Score: 0.002
-
Clostridium septicum septicemia with identical metastatic myonecroses in a granulocytopenic patient. Infectious disease emergency. Am J Med. 1985 Aug; 79(2):256-8.
Score: 0.002
-
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation. 2005 Jul 26; 112(4):563-71.
Score: 0.002
-
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism. 2005 Jul; 54(7):939-46.
Score: 0.002
-
Paternal age and intelligence: implications for age-related genomic changes in male germ cells. Psychiatr Genet. 2005 Jun; 15(2):117-25.
Score: 0.002
-
A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health. 2005 Jun; 64(3):206-21.
Score: 0.002
-
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
Score: 0.002
-
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 Apr; 60(4):471-5.
Score: 0.002
-
Relationship between body height and dementia. Am J Geriatr Psychiatry. 2005 Feb; 13(2):116-23.
Score: 0.002
-
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004 Sep; 19(9):898-905.
Score: 0.002
-
Treating dyslipidemia in high-risk patients: case reviews and discussion. Postgrad Med. 2004 Sep; 116(3 Suppl):21-8.
Score: 0.002
-
Evaluation of hyponatremia: a little physiology goes a long way. Cleve Clin J Med. 2004 Aug; 71(8):639-50.
Score: 0.002
-
Effect of contrast enhancement on measurement of carotid artery intimal medial thickness. Vasc Med. 2004 Feb; 9(1):7-12.
Score: 0.002
-
Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation. 2004 Feb 03; 109(4):471-5.
Score: 0.002
-
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
Score: 0.002
-
Cardiovascular disease among Alaska Natives: a review of the literature. Int J Circumpolar Health. 2003 Dec; 62(4):343-62.
Score: 0.002
-
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
Score: 0.002
-
The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr. 2003 Nov; 8(11):824-33.
Score: 0.002
-
Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep; 4(3):177-85.
Score: 0.002
-
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15; 92(2):152-60.
Score: 0.002
-
Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med. 2003 Jul 14; 163(13):1597-600.
Score: 0.002
-
Validation of the modified telephone interview for cognitive status (TICS-m) in Hebrew. Int J Geriatr Psychiatry. 2003 May; 18(5):381-6.
Score: 0.002
-
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
Score: 0.002
-
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C.
Score: 0.002
-
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan; 26(1):18-24.
Score: 0.002
-
Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord. 2003; 15(2):79-87.
Score: 0.002
-
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
Score: 0.002
-
Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. Am J Clin Nutr. 2002 Dec; 76(6):1230-6.
Score: 0.002
-
A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov; 57(11):M757-61.
Score: 0.002
-
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
Score: 0.002
-
Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002 Apr-Jun; 16(2):73-80.
Score: 0.001
-
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
Score: 0.001
-
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002 Jan-Feb; 9(1):16-22.
Score: 0.001
-
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
Score: 0.001
-
Accidental hypothermia: a community hospital perspective. Postgrad Med. 1981 Nov; 70(5):42-9.
Score: 0.001
-
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
Score: 0.001
-
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001 Jul; 157(1):137-44.
Score: 0.001
-
Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am J Clin Nutr. 2001 Jul; 74(1):33-43.
Score: 0.001
-
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 2001 May; 141(5):722-6.
Score: 0.001
-
Clinical and psychosocial factors associated with achievement of treatment goals in adolescents with diabetes mellitus. J Adolesc Health. 2001 May; 28(5):377-85.
Score: 0.001
-
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001 05; 86(5):1890-7.
Score: 0.001
-
Mitochondria and the heart. Curr Opin Cardiol. 2001 May; 16(3):201-10.
Score: 0.001
-
Assessing health status quality of life in ALS: comparison of the SIP/ALS-19 with the ALS Functional Rating Scale and the Short Form-12 Health Survey. ALS C.A.R.E. Study Group. Clinical Assessement, Research, and Education. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001 Mar; 2(1):31-7.
Score: 0.001
-
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001 Jan; 41(1):70-8.
Score: 0.001
-
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001; 17(1):43-50.
Score: 0.001
-
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000 Sep; 49(9):1234-8.
Score: 0.001
-
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 2000 Aug 15; 86(4):406-11.
Score: 0.001
-
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000 Jul 15; 86(2):221-3.
Score: 0.001
-
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000 Jul 15; 86(2):250-2.
Score: 0.001
-
High-molecular-weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men. J Nutr. 2000 Jul; 130(7):1705-10.
Score: 0.001
-
Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. J Pediatr. 2000 Jul; 137(1):107-13.
Score: 0.001
-
Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA. 2000 Jun 21; 283(23):3089-94.
Score: 0.001
-
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr. 2000 Jun; 71(6):1433-8.
Score: 0.001
-
Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases. J Infect Dis. 2000 Jun; 181 Suppl 3:S430-1.
Score: 0.001
-
Incorporation of lean red meat into a National Cholesterol Education Program Step I diet: a long-term, randomized clinical trial in free-living persons with hypercholesterolemia. J Am Coll Nutr. 2000 Jun; 19(3):351-60.
Score: 0.001
-
Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol. 2000 Feb 15; 85(4):451-6.
Score: 0.001
-
Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women. J Am Coll Nutr. 2000 Feb; 19(1):23-30.
Score: 0.001
-
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000 Feb; 85(2):720-6.
Score: 0.001
-
Bile acid excretion and patterns of fatty acid absorption in formula-fed premature infants. Pediatrics. 1980 Jan; 65(1):132-8.
Score: 0.001
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol. 2000 Jan; 23(1):39-46.
Score: 0.001
-
The efficacy of magnetic resonance imaging in acute knee injuries. Clin J Sport Med. 2000 Jan; 10(1):34-9.
Score: 0.001
-
Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant. 1999 Dec; 24(12):1291-7.
Score: 0.001
-
Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Am J Cardiol. 1999 Nov 15; 84(10):1198-203.
Score: 0.001
-
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med. 1999 Jul; 17(1):18-23.
Score: 0.001
-
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999 Jan 13; 281(2):137-44.
Score: 0.001
-
Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 1999 Jan 04; 35(1):77-84.
Score: 0.001
-
Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999 Jan 01; 45(1):32-40.
Score: 0.001
-
Validation of a Hebrew selective reminding test. Isr J Psychiatry Relat Sci. 1999; 36(1):11-7.
Score: 0.001
-
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998 Dec; 18(12):1942-7.
Score: 0.001
-
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998 Sep; 47(9):1097-104.
Score: 0.001
-
Mitochondria in neuromuscular disorders. Biochim Biophys Acta. 1998 Aug 10; 1366(1-2):199-210.
Score: 0.001
-
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 Aug; 155(8):1080-6.
Score: 0.001
-
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol. 1998 Aug 01; 82(3):311-6.
Score: 0.001
-
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998 Jul; 14(1):59-70.
Score: 0.001
-
Short-term effects of coping skills training as adjunct to intensive therapy in adolescents. Diabetes Care. 1998 Jun; 21(6):902-8.
Score: 0.001
-
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
Score: 0.001
-
Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). Eur J Hum Genet. 1998 Mar-Apr; 6(2):176-80.
Score: 0.001
-
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998 Feb; 27(2):267-74; discussion 274-5.
Score: 0.001
-
Olestra's effect on vitamins D and E in humans can be offset by increasing dietary levels of these vitamins. J Nutr. 1997 08; 127(8 Suppl):1666S-1685S.
Score: 0.001
-
Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design. Pharmacoeconomics. 1997 Aug; 12(2 Pt 2):278-85.
Score: 0.001
-
Fiber intake and risk of developing non-insulin-dependent diabetes mellitus. JAMA. 1997 Jun 11; 277(22):1761; author reply 1762.
Score: 0.001
-
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
Score: 0.001
-
Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska Natives. Int J Cancer. 1997 Apr 10; 71(2):218-22.
Score: 0.001
-
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry. 1997 Feb; 154(2):205-10.
Score: 0.001
-
Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull. 1997; 23(1):131-45.
Score: 0.001
-
Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon-Kuskokwim Delta region of Alaska. Pediatr Infect Dis J. 1996 Nov; 15(11):986-92.
Score: 0.001
-
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
Score: 0.001
-
The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996 Sep-Oct; 18(5):853-63.
Score: 0.001
-
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14.
Score: 0.001
-
Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry. 1996 Jun; 153(6):806-11.
Score: 0.001
-
Dihydrorhodamine 123 identifies impaired mitochondrial respiratory chain function in cultured cells harboring mitochondrial DNA mutations. J Histochem Cytochem. 1996 Jun; 44(6):571-9.
Score: 0.001
-
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
Score: 0.001
-
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996 Jan 10; 275(2):128-33.
Score: 0.001
-
Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res. 1995 Nov 29; 59(1-2):127-36.
Score: 0.001
-
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res. 1995 Sep; 17(1):25-33.
Score: 0.001
-
A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma. 1995 Jun; 18(1-2):145-52.
Score: 0.001
-
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995 May; 15(5):678-82.
Score: 0.001
-
Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. J Infect Dis. 1995 Mar; 171 Suppl 1:S50-2.
Score: 0.001
-
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995 Jan 20; 112(2):223-35.
Score: 0.001
-
Analysis of cybrids harboring MELAS mutations in the mitochondrial tRNA(Leu(UUR)) gene. Muscle Nerve Suppl. 1995; 3:S119-23.
Score: 0.001
-
Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J Neuropsychiatry Clin Neurosci. 1995; 7(1):76-81.
Score: 0.001
-
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995 Jan 01; 75(1):34-9.
Score: 0.001
-
A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 1994 Sep-Oct; 5(5):243-6.
Score: 0.001
-
Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens. J Infect Dis. 1994 Sep; 170(3):510-6.
Score: 0.001
-
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry. 1994 Jun 15; 35(12):909-12.
Score: 0.001
-
Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
Score: 0.001
-
Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem. 1994 Apr; 62(4):1516-23.
Score: 0.001
-
Myocardial viability in asynergic regions subtended by occluded coronary arteries: relation to the status of collateral flow in patients with chronic coronary artery disease. J Am Coll Cardiol. 1994 Mar 15; 23(4):860-8.
Score: 0.001
-
Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994 Mar 15; 73(8):527-33.
Score: 0.001
-
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 Mar; 151(3):390-6.
Score: 0.001
-
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res. 1994 Feb; 11(3):217-24.
Score: 0.001
-
Effects of ipsapirone in healthy subjects: a dose-response study. Psychopharmacology (Berl). 1994 Feb; 114(1):155-60.
Score: 0.001
-
Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls. Am J Med. 1993 Dec; 95(6):589-94.
Score: 0.001
-
Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
Score: 0.001
-
Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993 Sep; 150(9):1337-42.
Score: 0.001
-
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry. 1993 Aug; 50(8):599-605.
Score: 0.001
-
Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. Am J Psychiatry. 1993 Mar; 150(3):435-42.
Score: 0.001
-
Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
Score: 0.001
-
Fine mapping of mitochondrial RNAs derived from the mtDNA region containing a point mutation associated with MELAS. Nucleic Acids Res. 1993 Feb 11; 21(3):657-62.
Score: 0.001
-
Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl). 1993; 112(1 Suppl):S90-4.
Score: 0.001
-
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1993; 7(2):98-104.
Score: 0.001
-
Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta. 1992 Dec 10; 1180(2):147-62.
Score: 0.001
-
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 1992 Nov; 44(2):153-65.
Score: 0.001
-
Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia. Arterioscler Thromb. 1992 Oct; 12(10):1146-52.
Score: 0.001
-
Pneumococcal endocarditis in Alaska natives. A population-based experience, 1978 through 1990. Arch Intern Med. 1992 Aug; 152(8):1641-5.
Score: 0.001
-
The mitochondrial tRNA(Leu)(UUR)) mutation in MELAS: a model for pathogenesis. Biochim Biophys Acta. 1992 Jul 17; 1101(2):206-9.
Score: 0.001
-
Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 1992 May; 42(2):101-10.
Score: 0.001
-
Agitation and postdexamethasone cortisol levels in Alzheimer's disease. Am J Psychiatry. 1992 Apr; 149(4):546-8.
Score: 0.001
-
Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr Res. 1992 Apr; 7(1):85-90.
Score: 0.001
-
Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Mol Cell Biol. 1992 Feb; 12(2):480-90.
Score: 0.001
-
Carbon disulfide poisoning: a review. Am Heart J. 1972 Jan; 83(1):100-14.
Score: 0.001
-
Effect of concurrent distraction on communication failures in schizophrenic patients. II. Medication status correlations. Schizophr Res. 1991 Sep; 5(2):153-9.
Score: 0.001
-
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
Score: 0.001
-
Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res. 1991 Sep; 5(2):161-6.
Score: 0.001
-
Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res. 1991 Apr; 37(1):47-56.
Score: 0.001
-
Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions. Psychopharmacology (Berl). 1991; 103(1):95-8.
Score: 0.001
-
Formula feeding of normal term and low birth weight infants. Pediatr Clin North Am. 1970 Nov; 17(4):913-28.
Score: 0.001
-
Nutritional requirements of infants and children with liver disease. Am J Clin Nutr. 1970 May; 23(5):604-13.
Score: 0.001
-
Monoclonal antibodies to proteins from cocksfoot grass (Dactylis glomerata) pollen: isolation and N-terminal sequence of a major allergen. Int Arch Allergy Appl Immunol. 1990; 91(4):419-25.
Score: 0.001
-
Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. Atherosclerosis. 1989 Oct; 79(2-3):157-66.
Score: 0.001
-
CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol Psychiatry. 1988 Oct; 24(6):710-2.
Score: 0.001
-
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull. 1988; 24(3):458-62.
Score: 0.001
-
LIMITATIONS IN THE USE OF ORAL HYPOGLYCEMIC AGENTS IN JUVENILE PATIENTS WITH DIABETES. J Pediatr. 1965 May; 66:844-56.
Score: 0.000
-
A STUDY OF BLOOD GLUCOSE AND KETONE BODIES AND PLASMA FREE FATTY ACIDS, CHOLESTEROL, PHOSPHOLIPIDS AND TOTAL LIPIDS IN JUVENILE DIABETES. J Pediatr. 1965 Feb; 66:313-21.
Score: 0.000
-
Venous leg ulceration: evaluation of zinc treatment, serum zinc and rate of healing. Clin Exp Dermatol. 1977 Dec; 2(4):395-9.
Score: 0.000
-
Primary acquired hypogammaglobulinemia and regional enteritis. Arch Intern Med. 1977 Sep; 137(9):1252-4.
Score: 0.000
-
The value of respiratory tract bacteriology in pneumococcal pneumonia among Navajo Indians. Am Rev Respir Dis. 1974 May; 109(5):577-8.
Score: 0.000
-
The response of blood glucose, ketones, and plasma nonesterified fatty acids to fasting and epinephrine injection in infants and children. J Pediatr. 1961 Dec; 59:836-47.
Score: 0.000